Lysine demethylase KDM4A associates with translation machinery and regulates protein synthesis

Cancer Discovery

Volumn 5, Issue 3, 2015, Pages 255-263

  van Rechem, Capucine ^a   Black, Joshua C ^a   Boukhali, Myriam ^a   Aryee, Martin J ^b   Gräslund, Susanne ^c   Haas, Wilhelm ^a   Benes, Cyril H ^a   Whetstine, Johnathan R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 8055; JIB 04; LYSINE K SPECIFIC DEMETHYLASE 4A; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; HISTONE DEMETHYLASE; HYDRAZONE DERIVATIVE; INITIATION FACTOR; JIB-04; KDM4A PROTEIN, HUMAN; LYSINE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; RIBOSOME PROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL FRACTIONATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG SENSITIVITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MTT ASSAY; PROTEIN DEPLETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TRANSLATION REGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; METHYLATION; RNA TRANSLATION;

AMINOPYRIDINES; DRUG RESISTANCE; HUMANS; HYDRAZONES; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LYSINE; METHYLATION; PEPTIDE CHAIN INITIATION, TRANSLATIONAL; PEPTIDE INITIATION FACTORS; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN KINASE INHIBITORS; RIBOSOMAL PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84924415145     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1326     Document Type: Article

References (25)

1. Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature 2014; 510: 283-7.
2. Su IH, Dobenecker MW, Dickinson E, Oser M, Basavaraj A, Marqueron R, et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005; 121: 425-36.
3. Donlin LT, Andresen C, Just S, Rudensky E, Pappas CT, Kruger M, et al. Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofi lament organization. Genes Dev 2012; 26: 114-9.
4. Van Rechem C, Whetstine JR. Examining the impact of gene variants on histone lysine methylation. Biochim Biophys Acta 2014; 1839: 1463-76.
5. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13: 343-57.
6. Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell 2012; 48: 491-507.
7. Black JC, Allen A, Van Rechem C, Forbes E, Longworth M, Tschop K, et al. Conserved antagonism between JMJD2A/KDM4A and HP1gamma during cell cycle progression. Mol Cell 2010; 40: 736-48.
8. Black JC, Manning AL, Van Rechem C, Kim J, Ladd B, Cho J, et al. KDM4A lysine demethylase induces site-specifi c copy gain and rereplication of regions amplifi ed in tumors. Cell 2013; 154: 541-55.
9. Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res 2013; 73: 2936-42.
10. Kim TD, Shin S, Berry WL, Oh S, Janknecht R. The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem 2012; 113: 1368-76.
11. Ting L, Rad R, Gygi SP, Haas W. MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics. Nat Methods 2011; 8: 937-40.
12. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4: 335-48.
13. Populo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci 2012; 13: 1886-918.
14. Van Rechem C, Black JC, Greninger P, Zhao Y, Donado C, Burrowes PD, et al. A coding single-nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors. Cancer Discov 2015;5:245-54.
15. Wang L, Chang J, Varghese D, Dellinger M, Kumar S, Best AM, et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat Commun 2013; 4: 2035.
16. Tzatsos A, Paskaleva P, Ferrari F, Deshpande V, Stoykova S, Contino G, et al. KDM2B promotes pancreatic cancer via Polycombdependent and-independent transcriptional programs. J Clin Invest 2013; 123: 727-39.
17. Ciruelos Gil EM. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev 2014; 40: 862-71.
18. Jerusalem G, Rorive A, Collignon J. Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that infl uence patient outcomes. Breast Cancer 2014; 6: 43-57.
19. Mabuchi S, Hisamatsu T, Kimura T. Targeting mTOR signaling pathway in ovarian cancer. Curr Med Chem 2011; 18: 2960-8.
20. Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res 2012; 18: 5290-303.
21. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009; 15: 3970-7.
22. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010; 141: 69-80.
23. Van Rechem C, Black JC, Abbas T, Allen A, Rinehart CA, Yuan GC, et al. The SKP1-Cul1-F-box and leucine-rich repeat protein 4 (SCF-FbxL4) ubiquitin ligase regulates lysine demethylase 4A (KDM4A)/Jumonji domaincontaining 2A (JMJD2A) protein. J Biol Chem 2011; 286: 30462-70.
24. Vistejnova L, Dvorakova J, Hasova M, Muthny T, Velebny V, Soucek K, et al. The comparison of impedance-based method of cell proliferation monitoring with commonly used metabolic-based techniques. Neuro Endocrinol Lett 2009; 30 (suppl 1): 121-7.
25. Bioinformatics and computational biology solutions using R and bioconductor. Gentleman R, Carey V, Huber W, Dudoit S, Irizarry R, editors. New York: Springer; 2005. p. 397-420.